Dr. Reddy’s Announces 42nd AGM via Video Conference and Final Dividend Details
TipRanks' Prime Week Sale - 70% Off
- Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions.
- Discover top stock picks and new investment opportunities through TipRanks' Smart Investor Newsletter.
Dr Reddy’s Laboratories ( (RDY) ) has provided an update.
Dr. Reddy’s Laboratories on June 20, 2026, filed a Form 6-K with the U.S. Securities and Exchange Commission, indicating it had circulated an intimation dated the same day regarding shareholder communications. The filing underscores the company’s ongoing compliance as a foreign private issuer with U.S. disclosure norms, reinforcing transparency for its global investor base.
In an accompanying communication to stock exchanges on June 20, 2026, the company reported publication of a newspaper advertisement announcing its 42nd Annual General Meeting to be held via video conference, along with the record date and details of the final dividend. The notice, also emailed to shareholders, signals continued use of virtual formats for governance events and provides investors with key information on meeting participation and dividend entitlement.
The most recent analyst rating on (RDY) stock is a Buy
with a $1540.00 price target.
To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock,
see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Neutral.
The score is driven mainly by solid but weakening fundamentals (margin/ROE compression and higher debt despite growth) and a balanced earnings-call outlook that points to FY27 margin recovery but highlights near-term profitability and working-capital risks. Technicals are neutral-to-soft and valuation support is limited given the P/E and low yield.
To see Spark’s full report on RDY stock,
click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories is an India-based pharmaceutical company headquartered in Hyderabad, Telangana, with its shares listed on the National Stock Exchange of India, BSE, the New York Stock Exchange and NSE IFSC. The company operates in the global generics and pharmaceutical sector, providing medicines and healthcare products to a wide range of stakeholders, including international investors and domestic shareholders.
Average Trading Volume: 2,355,214
Technical Sentiment Signal: Buy
Current Market Cap: $11.25B
See more insights into RDY stock on TipRanks’ Stock Analysis page.
